AAPL340.08+3.17 (+0.94%) ▲|ABBV263.20+6.29 (+2.45%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|AAPL340.08+3.17 (+0.94%) ▲|ABBV263.20+6.29 (+2.45%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|
21.2 C
New York
Wednesday, July 29, 2026

Tag: bone

newssourceFORcompanyinformationcontent1releasesmarket

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2026

The Annual General Meeting of Hofseth BioCare ASA for 2026 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 30 June 2026 at 11:00 CEST.

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

In HelloNation, Periodontics Expert Dr. Scott Kissel of Manhattan, NY, Details Why Microsurgical Techniques Matter in Periodontal Care

The article explains how precision-focused periodontal procedures can support tissue preservation, improve healing, and patient comfort.MANHATTAN, N.Y., June 6, 2026 /PRNewswire/ -- Why is...

Gift of Life Marrow Registry Gala Celebrates First-Time Meetings Between Two Transplant Recipients and Their Lifesaving Donors

Gift of Life Marrow Registry hosted its annual NYC Gala, where two transplant recipients, including a 13-year-old boy, were united with their donors.

HelloNation Highlights Deep Cleaning for Gum Disease Prevention With Dental Expert Dr. John Morgan Jackson III, D.M.D.

The article outlines how deep cleaning and routine care address gum disease and protect long-term oral health.LAGRANGE, Ga., June 4, 2026 /PRNewswire/ -- Why...

Gujarat becomes the New Hub in Organ Transplantation

Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Further clinical efficacy and pharmacology data also to be presented 
Further clinical efficacy and pharmacology data also to be presented

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBone

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers